|
[1]FUKUI H, SAITO H, UENO Y, et al.Evidence-based clinical practice guidelines for liver cirrhosis 2015[J].J Gastroenterol, 2016, 51 (7) :629-650.
|
|
[2]QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature, 2010, 464 (7285) :59-65.
|
|
[3]MIURA K, OHNISHI H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (23) :7381-7391.
|
|
[4]WIEST R, ALBILLOS A, TRAUNER M, et al.Targeting the gutliver axis in liver disease[J].J Hepatol, 2017, 67 (5) :1084-1103.
|
|
[5]TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.
|
|
[6]SCHNABL B, BRENNER DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology, 2014, 146 (6) :1513-1524.
|
|
[7]BAJAJ JS, BETRAPALLY NS, GILLEVET PM.Decompensated cirrhosis and microbiome interpretation[J].Nature, 2015, 525 (7569) :e1-e2.
|
|
[8]BAJAJ JS, HEUMAN DM, HYLEMON PB, et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol, 2014, 60 (5) :940-947.
|
|
[9]GARCIA-PAGAN JC, GRACIA-SANCHO J, BOSCH J.Functional aspects on the pathophysiology of portal hypertension in cirrhosis[J].JHepatol, 2012, 57 (2) :458-461.
|
|
[10]MOGHADAMRAD S, MCCOY KD, GEUKING MB, et al.Attenuated portal hypertension in germ-free mice:Function of bacterial flora on the development of mesenteric lymphatic and blood vessels[J].Hepatology, 2015, 61 (5) :1685-1695.
|
|
[11]QIN N, YANG F, LI A, et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature, 2014, 513 (7516) :59-64.
|
|
[12]QUEVRAIN E, MAUBERT MA, MICHON C, et al.Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease[J].Gut, 2016, 65 (3) :415-425.
|
|
[13]KANG DJ, BETRAPALLY NS, GHOSH SA, et al.Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice[J].Hepatology, 2016, 64 (4) :1232-1248.
|
|
[14]AHLUWALIA V, BETRAPALLY NS, HYLEMON PB, et al.Impaired gut-liver-brain axis in patients with cirrhosis[J].Sci Rep, 2016, 6:26800.
|
|
[15]BAJAJ JS, BETRAPALLY NS, HYLEMON PB, et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology, 2015, 62 (4) :1260-1271.
|
|
[16]RIGGIO O, MANNAIONI G, RIDOLA L, et al.Peripheral and splanchnic indole and oxindole levels in cirrhotic patients:A study on the pathophysiology of hepatic encephalopathy[J].Am J Gastroenterol, 2010, 105 (6) :1374-1381.
|
|
[17]MONTAGNESE S, BIANCARDI A, SCHIFF S, et al.Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis[J].Hepatology, 2011, 53 (2) :558-566.
|
|
[18]HUANG R, NI JJ, GAO Y.The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J].J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.
|
|
[19]LOO TM, KAMACHI F, WATANABE Y, et al.Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J].Cancer Discov, 2017, 7 (5) :522-538.
|
|
[20]ZHOU LX, HAN T, LIU BW, et al.A preliminary analysis of composition and structure of intestinal microbiota in patients with liver cirrhosis or hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (9) :1740-1744. (in Chinese) 周冷潇, 韩涛, 刘保文, 等.肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析[J].临床肝胆病杂志, 2017, 33 (9) :1740-1744.
|
|
[21]HACKSTEIN CP, ASSMUS LM, WELZ M, et al.Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis[J].Gut, 2017, 66 (3) :507-518.
|
|
[22]CARNEVALE R, RAPARELLI V, NOCELLA C, et al.Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].J Hepatol, 2017, 67 (5) :950-956.
|
|
[23]MUNOZ L, JOSE BORRERO M, UBEDA M, et al.Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis[J].Hepatology, 2012, 56 (5) :1861-1869.
|
|
[24]STEIB CJ, HARTMANN AC, V HESLER C, et al.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis[J].Lab Invest, 2010, 90 (7) :1024-1032.
|
|
[25]DOI H, IYER TK, CARPENTER E, et al.Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population[J].Hepatology, 2012, 55 (3) :709-719.
|
|
[26]LEVY M, THAISS CA, ZEEVI D, et al.Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NL-RP6 inflammasome signaling[J].Cell, 2015, 163 (6) :1428-1443.
|
|
[27]WIEST R, LAWSON M, GEUKING M.Pathological bacterial translocation in liver cirrhosis[J].J Hepatol, 2014, 60 (1) :197-209.
|
|
[28]BELLOT P, GARCIA-PAGAN JC, FRANCES R, et al.Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis[J].Hepatology, 2010, 52 (6) :2044-2052.
|
|
[29]TELTSCHIK Z, WIEST R, BEISNER J, et al.Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J].Hepatology, 2012, 55 (4) :1154-1163.
|
|
[30]RYAN KK, TREMAROLI V, CLEMMENSEN C, et al.FXR is a molecular target for the effects of vertical sleeve gastrectomy[J].Nature, 2014, 509 (7499) :183-188.
|
|
[31]JIANG C, XIE C, LI F, et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J].J Clin Invest, 2015, 125 (1) :386-402.
|
|
[32]ARAB JP, KARPEN SJ, DAWSON PA, et al.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J].Hepatology, 2017, 65 (1) :350-362.
|
|
[33]PARSEUS A, SOMMER N, SOMMER F, et al.Microbiota-induced obesity requires farnesoid X receptor[J].Gut, 2017, 66 (3) :429-437.
|
|
[34]RIDLON JM, ALVES JM, HYLEMON PB, et al.Cirrhosis, bile acids and gut microbiota:Unraveling a complex relationship[J].Gut Microbes, 2013, 4 (5) :382-387.
|
|
[35]KALAMBOKIS GN, MOUZAKI A, RODI M, et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :815-818.
|
|
[36]ZHU Q, ZOU L, JAGAVELU K, et al.Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice[J].JHepatol, 2012, 56 (4) :893-899.
|
|
[37]KANG SH, LEE YB, LEE JH, et al.Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J].Aliment Pharmacol Ther, 2017, 46 (9) :845-855.
|
|
[38]LIANG S, WEBB T, LI Z.Probiotic antigens stimulate hepatic natural killer T cells[J].Immunology, 2014, 141 (2) :203-210.
|
|
[39]LUNIA MK, SHARMA BC, SHARMA P, et al.Probiotics prevent hepatic encephalopathy in patients with cirrhosis:A randomized controlled trial[J].Clin Gastroenterol Hepatol, 2014, 12 (6) :1003-1008.e1.
|
|
[40]BAJAJ JS, GILLEVET PM, PATEL NR, et al.A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy[J].Metab Brain Dis, 2012, 27 (2) :205-215.
|
|
[41]TAUXE WM, HAYDEK JP, REBOLLEDO PA, et al.Fecal microbiota transplant for Clostridium difficile infection in older adults[J].Therap Adv Gastroenterol, 2016, 9 (3) :273-281.
|
|
[42]GARCIA-LEZANA T, RAURELL I, BRAVO M, et al.Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis[J].Hepatology, 2018, 67 (4) :1485-1498.
|
|
[43]VERBEKE L, FARRE R, TREBICKA J, et al.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats[J].Hepatology, 2014, 59 (6) :2286-2298.
|
DownLoad: